Neurofeedback for Depression
(CNF-RNT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new method to assist individuals with major depressive disorder (MDD) who frequently experience negative thinking patterns. Researchers use a technique called real-time fMRI neurofeedback, which provides feedback signals to the brain to help alter connections in specific brain areas. Participants are divided into two groups: one receives real feedback (active neurofeedback), while the other receives fake feedback (sham neurofeedback) for comparison. This trial targets young adults diagnosed with MDD who struggle with repetitive negative thoughts. Those who have experienced depression and often brood may find this trial suitable. As an unphased trial, it offers a unique opportunity to contribute to innovative research and potentially benefit from cutting-edge treatment.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot start new psychotropic medications or therapy for depression or anxiety less than a month before joining. Also, you cannot use more than three psychotropic medications or certain cardiovascular medications.
What prior data suggests that real-time fMRI neurofeedback is safe for treating depression?
Research has shown that real-time fMRI neurofeedback is generally well-tolerated. Studies have found this feedback to be safe for treating mental health conditions like depression. Most research comparing real neurofeedback to sham treatments has identified no major safety concerns. Participants typically manage the treatment well, with few reporting significant side effects. This suggests that the neurofeedback used in this trial is typically safe for individuals with major depressive disorder.12345
Why are researchers excited about this trial?
Researchers are excited about neurofeedback for depression because it offers a non-invasive way to potentially improve mental health by directly targeting brain activity. Unlike traditional treatments like antidepressants or therapy, which often require time to show effects, neurofeedback provides immediate feedback on brain function, helping individuals recognize and modify their repetitive negative thought patterns. This approach could lead to faster symptom relief by enhancing the brain's connectivity in real-time, offering a novel mechanism of action compared to existing options.
What evidence suggests that this trial's treatments could be effective for depression?
Research has shown that real-time brain activity feedback, known as rtfMRI-nf, holds promise for treating depression. In this trial, participants will receive either Active neurofeedback, which provides feedback signals from the repetitive negative thinking (RNT)-related brain functional connectivity, or Sham neurofeedback, which provides artificially generated feedback signals. In one study, 75% of participants reported feeling better four weeks after treatment. Another study found that up to 100% of people with major depression showed behavioral improvements. These results suggest that this type of feedback may help reduce negative thinking in depression by altering brain connectivity.12356
Are You a Good Fit for This Trial?
This trial is for young adults with major depressive disorder (MDD) who often have repetitive negative thoughts. Participants must be within a certain age range, typically considered 'young adult', and should meet specific criteria for MDD and high levels of such thoughts.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo real-time fMRI neurofeedback sessions to modulate brain connectivity related to repetitive negative thinking
Follow-up
Participants are monitored for changes in functional connectivity and depression severity
What Are the Treatments Tested in This Trial?
Interventions
- Active neurofeedback
- Sham neurofeedback
Find a Clinic Near You
Who Is Running the Clinical Trial?
Laureate Institute for Brain Research, Inc.
Lead Sponsor
National Institute of General Medical Sciences (NIGMS)
Collaborator